Implementation of macrocycle conjugated antibodies for tumour-targetting

Abstract
Monoclonal antibodies may be selectively functionalised with macrocyclic ligands, permitting the transport of an imaging or cytotoxic metal radionuclide specifically to a tumour. Antibodies conjugated to [13] and [14]-membered tetraazamacrocycles allow 64Cu or 67Cu labelled antibody to be used for imaging or therapy.